• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Cerecor Inc.

    9/21/21 4:51:43 PM ET
    $CERC
    Major Pharmaceuticals
    Health Care
    Get the next $CERC alert in real time by email
    SC 13G 1 p13ga.htm SCHEDULE 13G
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.

    Securities and Exchange Commission, Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No._)*

    (Name of Issuer)

    Avalo Therapeutics, Inc.

    (Title of Class of Securities)

    Common Stock, $0.001 Par Value Per Share

    (CUSIP Number)

    05338F108

    (Date of Event Which Requires Filing of this Statement)

    September 17, 2021

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:

    [  ] Rule 13d-1(b)

    [ x ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).



    CUSIP No. 05338F108
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              6,008,850 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       6,008,850 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    6,008,850 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.4% (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     



    CUSIP No. 05338F108
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              6,008,850 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       6,008,850 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    6,008,850 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.4% (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     



    CUSIP No. 05338F108
    (1) Names of reporting persons    Point72 Hong Kong Limited
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Hong Kong
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              846 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       846 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    846 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 05338F108
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              6,009,696 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       6,009,696 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    6,009,696 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.4% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     





    Item 1(a) Name of issuer:

    Avalo Therapeutics, Inc.

    Item 1(b) Address of issuer's principal executive offices:

    540 Gaither Road, Suite 400, Rockville, Maryland 20850

    2(a) Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, $0.001 par value per share
    (“Shares”), of the Issuer held by certain investment funds it manages; (ii) Point72 Capital
    Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by certain
    investment funds managed by Point72 Asset Management; (iii) Point72 Hong Kong Limited
    (“Point72 Hong Kong”) with respect to Shares held by certain investment funds it manages; and
    (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset
    Management, Point72 Capital Advisors Inc., and Point72 Hong Kong.
    Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Hong Kong,
    and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is
    filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed
    to file this Schedule 13G jointly in accordance with the provisions of
    Rule 13d-1(k) of the Act.

    2(b) Address or principal business office or, if none, residence:

    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902; and (ii) Point72 Hong Kong is 12th Floor, Chater House,
    8 Connaught Road Central, Hong Kong.

    2(c) Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital
    Advisors Inc. is a Delaware corporation. Point72 Hong Kong is a Hong Kong
    limited liability company. Mr. Cohen is a United States citizen.

    2(d) Title of class of securities:

    Common Stock, $0.001 Par Value Per Share

    2(e) CUSIP Number:

    05338F108

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on September 20, 2021:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 6,008,850
    (b) Percent of class: 5.4% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 6,008,850 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 6,008,850

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 6,008,850
    (b) Percent of class: 5.4% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 6,008,850 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 6,008,850

    3. Point72 Hong Kong Limited
    (a) Amount beneficially owned: 846
    (b) Percent of class: <0.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 846 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 846


    4. Steven A. Cohen
    (a) Amount beneficially owned: 6,009,696
    (b) Percent of class: 5.4% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 6,009,696 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 6,009,696

    Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Hong Kong,
    and Mr. Cohen own directly no Shares. Pursuant to an investment management
    agreement, Point72 Asset Management maintains investment and voting power
    with respect to the securities held by certain investment funds it manages.
    Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management.
    Pursuant to an investment management agreement, Point72 Hong Kong maintains
    investment and voting power with respect to the securities held by certain investment
    funds it manages. Mr. Cohen controls each of Point72 Asset Management,
    Point72 Capital Advisors Inc., and Point72 Hong Kong. By reason of the provisions
    of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, each of
    (i) Point72 Asset Management, Point72 Capital Advisors Inc. and Mr. Cohen
    may be deemed to beneficially own 6,008,850 Shares (constituting approximately
    5.4% of the Shares outstanding), and (ii) Point72 Hong Kong and Mr. Cohen may
    be deemed to beneficially own 846 Shares (constituting <0.1% of the Shares
    outstanding). Each of Point72 Asset Management, Point72 Capital Advisors Inc.,
    Point72 Hong Kong, and Mr. Cohen disclaims beneficial ownership of any of
    the securities covered by this statement.

    Item 5.  Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [  ].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.

    Not applicable

    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities
    referred to above were not acquired and are not held for the purpose of or with the
    effect of changing or influencing the control of the issuer of the securities and were
    not acquired and are not held in connection with or as a participant in any transaction
    having that purpose or effect, other than activities solely in connection with a nomination
    under§ 240.14a-11.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: September 21, 2021


    POINT72 ASSET MANAGEMENT, L.P.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 CAPITAL ADVISORS, INC.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 HONG KONG LIMITED

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    STEVEN A. COHEN

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person




    Get the next $CERC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CERC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Cerecor Inc. (Amendment)

      SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      10/14/21 9:01:02 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Cerecor Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      9/21/21 4:51:43 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Cerecor Inc. (Amendment)

      SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      9/17/21 3:04:41 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

      Name change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates advancing in development with eight ongoing clinical programsFour therapies with Rare Pediatric Disease Designation with each potentially eligible for a Priority Review Voucher upon approvalMultiple data readouts anticipated in the second half of 2021 WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significa

      8/26/21 7:30:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

      Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsAnnounced plans to explore CERC-002 in patients with moderate-to-severe ulcerative colitis refractory to anti-TNF alpha therapiesCompleted $35 million debt financing that extends cash runway and supports multiple clinical catalysts anticipated in the second half of 2021 ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of tre

      8/2/21 4:01:00 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

      ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced that it has completed its second drawdown of $10 million under its previously announced $35 million debt financing agreement with Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon"). This second tranche was made available in connection with the Company's successful positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002, an investigational first-in-class fully huma

      8/2/21 7:30:00 AM ET
      $CERC
      $HRZN
      Major Pharmaceuticals
      Health Care
      Finance: Consumer Services
      Finance

    $CERC
    Financials

    Live finance-specific insights

    See more
    • Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients

      Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsMean reduction in LIGHT levels of approximately 80% compared to baseline signify a dramatic and rapid reduction of LIGHT levels correlating to the pharmacodynamic effect of CERC-002Clinically meaningful endoscopic improvement in 75% (3/4) of subjects, as determined by colonoscopy (SES-CD score)CERC-002 was well tolerated with no drug-related severe adverse eventsCohort 2 (3.0 mg/kg dose) fully enrolled; complete data anticipated in 2H21Promising initial results support expansion to p

      7/26/21 4:01:00 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Maher Illya Keith

      3 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/22/21 7:45:39 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Bruhn Suzanne Louise

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/4/21 4:48:25 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Gutry Phil

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/4/21 4:45:42 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Cerecor with a new price target

      Cantor Fitzgerald initiated coverage of Cerecor with a rating of Overweight and set a new price target of $7.00

      6/4/21 7:42:32 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor upgraded by Maxim Group with a new price target

      Maxim Group upgraded Cerecor from Hold to Buy and set a new price target of $7.00

      4/21/21 9:51:06 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Jefferies initiated coverage on Cerecor with a new price target

      Jefferies initiated coverage of Cerecor with a rating of Buy and set a new price target of $4.00

      4/20/21 7:17:47 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Leadership Updates

    Live Leadership Updates

    See more
    • Panbela Appoints Industry Veteran, Garry A. Weems, PharmD, as Vice President of Clinical Development & Medical Affairs

      MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the appointment of Garry A. Weems, PharmD, as its Vice President of Clinical Development and Medical Affairs. Dr. Weems joins Panbela from Cerecor, Inc. (Nasdaq:CERC) where he was Senior Director of Clinical Development. “Panbela has made considerable progress in the last 12-months and is now at a critical juncture as we begin to plan more expansive development of SBP-101,” said Jennifer Simpson, Chief Executive Officer at Panbela. “Garry’s substantial backgroun

      3/15/21 8:00:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Appoints Schond L. Greenway as Chief Financial Officer

      ROCKVILLE, Md. and CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced the appointment of Schond L. Greenway as Chief Financial Officer, effective March 1, 2021. Mr. Greenway comes to Cerecor with over 20 years’ experience in investment banking, finance and corporate advisory and investment analysis in the life sciences and financial services industries. Chris Sullivan, who has served as the Company’s Interim Chief Financial Officer for the past year, will continue with the Company as its Chief Accounting

      3/1/21 7:00:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    SEC Filings

    See more
    • Cerecor Inc. filed SEC Form 8-K: Leadership Update

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      10/18/21 4:11:35 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      9/15/21 4:44:34 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 424B5 filed by Cerecor Inc.

      424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)

      9/15/21 4:41:54 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care